Changes in specialized blood vessels in lymph nodes and their role in cancer metastasis

Journal of Translational Medicine

Volumn 10, Issue 1, 2012, Pages

  Lee, Ser Yee ^a,b   Chao Nan, Qian ^c,d   Seng, Ooi Aik ^c   Peiyi, Chen ^e   Bernice, Wong Hui Min ^b   Swe, Myint Swe ^b   Chii, Wong Jing ^b   Jacqueline, Hwang Siok Gek ^a   Chee, Soo Khee ^a,b  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^c VAN ANDEL RESEARCH INSTITUTE   (United States)

^d SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Angiogenesis; Cancer metastasis; High endothelial venules; Lymph nodes

Indexed keywords

ARTICLE; BLOOD VESSEL; BLOOD VESSEL DENSITY; BLOOD VESSEL PARAMETERS; CANCER GROWTH; CANCER STAGING; CERVICAL LYMPH NODE; CONTROLLED STUDY; DISEASE FREE INTERVAL; HIGH ENDOTHELIAL VENULE; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MAJOR CLINICAL STUDY; METASTASIS; NECK DISSECTION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PROGNOSIS; SURVIVAL TIME; TONGUE CARCINOMA; VENULE;

CASE-CONTROL STUDIES; DISEASE-FREE SURVIVAL; ENDOTHELIUM, VASCULAR; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPH NODES; LYMPHATIC METASTASIS; NEOPLASMS; VENULES;

EID: 84866941862     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-10-206     Document Type: Article

References (55)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun M. Cancer statistics. CA Cancer J Clin 2008, 58:71-96. 10.3322/CA.2007.0010, 18287387.
2. Silverman SJ. Demographics and occurrence of oral and pharyngeal cancers. The outcomes, the trends, the challenge. J Am Dent Assoc 2001, 132:7S-11S.
3. Edwards B, Brown M, Wingo P, Howe H, Ward E, Ries L, Schrag D, Jamison P, Jemal A, Wu X, et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 2005, 97:1407-1427. 10.1093/jnci/dji289, 16204691.
4. Cabanas R. An approach for the treatment of penile carcinoma. Cancer 1977, 39:456-466. 10.1002/1097-0142(197702)39:2<456::AID-CNCR2820390214>3.0.CO;2-I, 837331.
5. Qian C, Berghuis B, Tsarfaty G, Bruch M, Kort E, Ditlev J, Tsarfaty I, Hudson E, Jackson D, Petillo D, et al. Preparing the "soil": the primary tumor induces vasculature reorganization in the sentinel lymph node before the arrival of metastatic cancer cells. Cancer Res 2006, 66:10365-10376. 10.1158/0008-5472.CAN-06-2977, 17062557.
6. Chung MK, Do IG, Jung E, Son YI. Jeong HS 2011, Baek CH: Lymphatic Vessels and High Endothelial Venules are Increased in the Sentinel Lymph Nodes of Patients with Oral Squamous Cell Carcinoma Before the Arrival of Tumor Cells. Ann Surg Oncol.
7. Nathanson SD. Insights into the mechanisms of lymph node metastasis. Cancer 2003, 98:413-423. 10.1002/cncr.11464, 12872364.
8. Martinet L, Garrido I, Filleron T, Le Guellec S, Bellard E, Fournie JJ, Rochaix P, Girard JP. Human solid tumors contain high endothelial venules: association with T- and B-lymphocyte infiltration and favorable prognosis in breast cancer. Cancer Res 2011, 71:5678-5687. 10.1158/0008-5472.CAN-11-0431, 21846823.
9. Hayasaka H, Taniguchi K, Fukai S, Miyasaka M. Neogenesis and development of the high endothelial venules that mediate lymphocyte trafficking. Cancer Sci 2010, 101:2302-2308. 10.1111/j.1349-7006.2010.01687.x, 20726857.
10. Qian CN, Resau JH, Teh BT. Prospects for vasculature reorganization in sentinel lymph nodes. Cell Cycle 2007, 6:514-517. 10.4161/cc.6.5.3931, 17329977.
11. Miyasaka M, Tanaka T. Lymphocyte trafficking across high endothelial venules: dogmas and enigmas. Nat Rev Immunol 2004, 4:360-370. 10.1038/nri1354, 15122201.
12. Liao S, Ruddle N. Synchrony of high endothelial venules and lymphatic vessels revealed by immunization. J Immunol 2006, 177:3369-3379.
13. Moussion C, Girard JP. Dendritic cells control lymphocyte entry to lymph nodes through high endothelial venules. Nature 2011, 479:542-546. 10.1038/nature10540, 22080953.
14. Ji RC. Lymph node lymphangiogenesis: a new concept for modulating tumor metastasis and inflammatory process. Histol Histopathol 2009, 24:377-384.
15. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410:50-56. 10.1038/35065016, 11242036.
16. Rosen PP, Saigo PE, Braun DW, Weathers E, DePalo A. Predictors of recurrence in stage I (T1N0M0) breast carcinoma. Ann Surg 1981, 193:15-25. 10.1097/00000658-198101000-00003, 1344996, 7458446.
17. Rosen PP, Lesser ML, Kinne DW, Beattie EJ. Discontinuous or "skip" metastases in breast carcinoma. Analysis of 1228 axillary dissections. Ann Surg 1983, 197:276-283. 10.1097/00000658-198303000-00006, 1352730, 6830335.
18. Leong SP. Paradigm shift of staging and treatment for early breast cancer in the sentinel lymph node era. Breast J 2006, 12:S128-S133. 10.1111/j.1075-122X.2006.00326.x, 16958992.
19. Greene FL. PD, Fleming ID: AJCC Cancer Staging Manual 2002, New York, NY: Springer, 6.
20. Lee SY, Qian CN, Ooi AS, Chen P, Tan VK, Chia CS, Hwang JS, Teh BT, Soo KC. 2011 Young Surgeon's Award Winner: high endothelial venules: a novel prognostic marker in cancer metastasis and the missing link?. Ann Acad Med Singapore 2012, 41:21-28.
21. Qian C, Zhang C, Guo X, Hong M, Cao S, Mai W, Min H, Zeng Y. Elevation of serum vascular endothelial growth factor in male patients with metastatic nasopharyngeal carcinoma. Cancer 2000, 88:255-261. 10.1002/(SICI)1097-0142(20000115)88:2<255::AID-CNCR2>3.0.CO;2-N, 10640954.
22. Sano D, Myers J. Metastasis of squamous cell carcinoma of the oral tongue. Cancer Metastasis Rev 2007, 26:645-662. 10.1007/s10555-007-9082-y, 17768600.
23. Balch C, Soong S, Gershenwald J, Thompson J, Reintgen D, Cascinelli N, Urist M, McMasters K, Ross M, Kirkwood J, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001, 19:3622-3634.
24. McGuire W. Prognostic factors for recurrence and survival in human breast cancer. Breast Cancer Res Treat 1987, 10:5-9. 10.1007/BF01806129, 3689982.
25. Harrison J, Dean P, El-Zeky F, Vander Zwaag R. From Dukes through Jass: pathological prognostic indicators in rectal cancer. Hum Pathol 1994, 25:498-505. 10.1016/0046-8177(94)90122-8, 8200644.
26. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003, 3:453-458. 10.1038/nrc1098, 12778135.
27. Skobe M, Hawighorst T, Jackson D, Prevo R, Janes L, Velasco P, Riccardi L, Alitalo K, Claffey K, Detmar M. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 2001, 7:192-198. 10.1038/84643, 11175850.
28. Jain RK, Munn LL, Fukumura D. Dissecting tumour pathophysiology using intravital microscopy. Nat Rev Cancer 2002, 2:266-276. 10.1038/nrc778, 12001988.
29. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001, 411:375-379. 10.1038/35077241, 11357145.
30. Weidner N. New paradigm for vessel intravasation by tumor cells. Am J Pathol 2002, 160:1937-1939. 10.1016/S0002-9440(10)61141-8, 1850816, 12057896.
31. Plate K. From angiogenesis to lymphangiogenesis. Nat Med 2001, 7:151-152. 10.1038/84579, 11175837.
32. Arnold D, Stein A. Personalized treatment of colorectal cancer 2012, 42-48. Switzerland: Basel, Suppl 1, Onkologie.
33. Hirakawa S, Kodama S, Kunstfeld R, Kajiya K, Brown L, Detmar M. VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J Exp Med 2005, 201:1089-1099. 10.1084/jem.20041896, 2213132, 15809353.
34. Stacker S, Caesar C, Baldwin M, Thornton G, Williams R, Prevo R, Jackson D, Nishikawa S, Kubo H, Achen M. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 2001, 7:186-191. 10.1038/84635, 11175849.
35. Mäkinen T, Jussila L, Veikkola T, Karpanen T, Kettunen M, Pulkkanen K, Kauppinen R, Jackson D, Kubo H, Nishikawa S, et al. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med 2001, 7:199-205. 10.1038/84651, 11175851.
36. Mandriota S, Jussila L, Jeltsch M, Compagni A, Baetens D, Prevo R, Banerji S, Huarte J, Montesano R, Jackson D, et al. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J 2001, 20:672-682. 10.1093/emboj/20.4.672, 145430, 11179212.
37. Fukumoto S, Morifuji M, Katakura Y, Ohishi M, Nakamura S. Endostatin inhibits lymph node metastasis by a down-regulation of the vascular endothelial growth factor C expression in tumor cells. Clin Exp Metastasis 2005, 22:31-38. 10.1007/s10585-005-3973-5, 16132576.
38. Roberts N, Kloos B, Cassella M, Podgrabinska S, Persaud K, Wu Y, Pytowski B, Skobe M. Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2. Cancer Res 2006, 66:2650-2657. 10.1158/0008-5472.CAN-05-1843, 16510584.
39. http://www.cancer.gov/cancertropics/factsheet/AvastinFactSheet.
40. Zwaans B, Bielenberg D. Potential therapeutic strategies for lymphatic metastasis. Microvasc Res 2007, 74:145-158. 10.1016/j.mvr.2007.08.006, 2525453, 17950368.
41. Escudier B, Eisen T, Stadler W, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai A, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-134. 10.1056/NEJMoa060655, 17215530.
42. Motzer R, Michaelson M, Redman B, Hudes G, Wilding G, Figlin R, Ginsberg M, Kim S, Baum C, DePrimo S, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006, 24:16-24. 10.1200/JCO.2005.02.2574, 16330672.
43. Faivre S, Demetri G, Sargent W, Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 2007, 6:734-745. 10.1038/nrd2380, 17690708.
44. Pitman KT. Sentinel node localization in head and neck tumors. Semin Nucl Med 2005, 35:253-256. 10.1053/j.semnuclmed.2005.05.004, 16150245.
45. Boardman K, Swartz M. Interstitial flow as a guide for lymphangiogenesis. Circ Res 2003, 92:801-808. 10.1161/01.RES.0000065621.69843.49, 12623882.
46. Halin C, Detmar M. An unexpected connection: lymph node lymphangiogenesis and dendritic cell migration. Immunity 2006, 24:129-131. 10.1016/j.immuni.2006.01.011, 16473825.
47. Boscacci RT, Pfeiffer F, Gollmer K, Sevilla AI, Martin AM, Soriano SF, Natale D, Henrickson S, von Andrian UH, Fukui Y, et al. Comprehensive analysis of lymph node stroma-expressed Ig superfamily members reveals redundant and nonredundant roles for ICAM-1, ICAM-2, and VCAM-1 in lymphocyte homing. Blood 2010, 116:915-925. 10.1182/blood-2009-11-254334, 3324225, 20395417.
48. Yeh J, Hiraoka N, Petryniak B, Nakayama J, Ellies L, Rabuka D, Hindsgaul O, Marth J, Lowe J, Fukuda M. Novel sulfated lymphocyte homing receptors and their control by a Core1 extension beta 1,3-N-acetylglucosaminyltransferase. Cell 2001, 105:957-969. 10.1016/S0092-8674(01)00394-4, 11439191.
49. Jerjes W, Upile T, Petrie A, Riskalla A, Hamdoon Z, Vourvachis M, Karavidas K, Jay A, Sandison A, Thomas GJ, et al. Clinicopathological parameters, recurrence, locoregional and distant metastasis in 115 T1-T2 oral squamous cell carcinoma patients. Head Neck Oncol 2010, 2:9. 10.1186/1758-3284-2-9, 2882907, 20406474.
50. Greenberg JS, El Naggar AK, Mo V, Roberts D, Myers JN. Disparity in pathologic and clinical lymph node staging in oral tongue carcinoma. Implication for therapeutic decision making. Cancer 2003, 98:508-515. 10.1002/cncr.11526, 12879467.
51. Kalnins IK, Leonard AG, Sako K, Razack MS, Shedd DP. Correlation between prognosis and degree of lymph node involvement in carcinoma of the oral cavity. Am J Surg 1977, 134:450-454. 10.1016/0002-9610(77)90376-2, 911028.
52. Chi J, Chang H, Haraldsen G, Jahnsen F, Troyanskaya O, Chang D, Wang Z, Rockson S, van de Rijn M, Botstein D, Brown P. Endothelial cell diversity revealed by global expression profiling. Proc Natl Acad Sci USA 2003, 100:10623-10628. 10.1073/pnas.1434429100, 196854, 12963823.
53. Nieder C, Ang K. Cervical lymph node metastases from occult squamous cell carcinoma. Curr Treat Options Oncol 2002, 3:33-40. 10.1007/s11864-002-0039-7, 12057085.
54. Baekkevold E, Roussigné M, Yamanaka T, Johansen F, Jahnsen F, Amalric F, Brandtzaeg P, Erard M, Haraldsen G, Girard J. Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules. Am J Pathol 2003, 163:69-79. 10.1016/S0002-9440(10)63631-0, 1868188, 12819012.
55. Kawashima H, Hirakawa J, Tobisawa Y, Fukuda M, Saga Y. Conditional gene targeting in mouse high endothelial venules. J Immunol 2009, 182:5461-5468. 10.4049/jimmunol.0802327, 2771617, 19380794.